Pipeline

By leveraging our deep expertise in protein drug discovery, our immunotherapy pipeline has been specifically curated to target clinically validated as well as emerging mechanisms, positioning our portfolio to pursue both best-in-class and first-in-class approaches.

ProgramMechanism of ActionLead IDLead OPIND EnablingClinic
BPT567
(PD1-IL18)
Immuno-oncology
 PD-1 blockade
+ tumor targeting
+ IL-18 signaling
IL-18 binding protein resistant

 

BPT567 is a human anti-programmed cell death protein 1 (PD-1) antibody site-specifically conjugated to an interleukin-18 (IL-18) protein variant payload with decreased binding affinity to the IL-18 binding protein (IL-18BP). Interleukin-18 (IL-18) is a pro-inflammatory cytokine able to trigger both innate and adaptive immune responses and is a potent inducer of interferon gamma (IFN-γ) secretion, making it an attractive candidate for cancer immunotherapy. IL-18BP is a secreted physiologic antagonist that binds IL-18 with high affinity and is induced by IFN-γ in a natural negative feedback loop that neutralizes IL-18 activity. The IL-18 protein payload of BPT567 has been engineered to resist neutralization by IL-18BP, therefore maintaining the desired immunostimulatory activity of IL-18 in the presence of IFN-γ -induced IL-18BP.

BPT567 has been designed to engage both PD‑1 and the IL-18 receptor (IL-18R) in tandem and to preferentially activate immune cells expressing both targets. Simultaneous binding to both receptors results in enhanced IL-18 potency due to cis-signaling i.e., the engagement of PD-1, and blockade of PD-1/PD-L1 interaction, with concurrent IL-18 signaling through the IL-18R on the same cell. In transgenic mice engineered to express human PD-1, BPT567 induces significantly stronger anti-tumor efficacy relative to an anti-PD-1 antibody alone, a non-targeted IL-18 immunoconjugate alone or the combination of the two agents. BPT567 has demonstrated anti-tumor activity in both immune checkpoint inhibitor (ICI)-sensitive and ICI-resistant non-clinical tumor models. As a result of its high anti-tumor potency and relative tumor selectivity demonstrated in non-clinical tumor models, BPT567 is designed to induce lower systemic IL-18R-mediated activation side effects compared to non-targeted IL-18 agents when administered at efficacious doses.

BPT567 is entering a first-in-human phase 1a/1b study in patients with locally advanced or metastatic solid tumors.

close x
BPT331TAP
(PD1-IL2TAP)
Immuno-oncology
 PD-1 blockade
+ tumor-selective activation
+ β/ γ-selective IL-2 signaling
α-dead β-enhanced
Conditionally activated in the TME

 

PD1-IL2TAP consists of Bright Peak’s enhanced IL-2 payload chemically conjugated to LZM009, an anti-PD-1 antibody now in late-stage clinical development, with an additional moiety that enables the IL-2 payload to be conditionally activated when encountering the tumor microenvironment (tumor activated payload or "TAP") for a potentially expanded therapeutic window and greater safety margin.
close x
 
Numerous undisclosed discovery assets in IO & Autoimmune disease

 

close x
DrugPhase
BPT567
(PD1-IL18)
Immuno-oncology
IND Enabling
BPT331TAP
(PD1-IL2TAP)
Immuno-oncology
Lead OP
 
Numerous undisclosed discovery assets in IO & Autoimmune disease
Lead OP

BPT567
(PD1-IL18)

BPT567 is a human anti-programmed cell death protein 1 (PD-1) antibody site-specifically conjugated to an interleukin-18 (IL-18) protein variant payload with decreased binding affinity to the IL-18 binding protein (IL-18BP). Interleukin-18 (IL-18) is a pro-inflammatory cytokine able to trigger both innate and adaptive immune responses and is a potent inducer of interferon gamma (IFN-γ) secretion, making it an attractive candidate for cancer immunotherapy. IL-18BP is a secreted physiologic antagonist that binds IL-18 with high affinity and is induced by IFN-γ in a natural negative feedback loop that neutralizes IL-18 activity. The IL-18 protein payload of BPT567 has been engineered to resist neutralization by IL-18BP, therefore maintaining the desired immunostimulatory activity of IL-18 in the presence of IFN-γ -induced IL-18BP.

BPT567 has been designed to engage both PD‑1 and the IL-18 receptor (IL-18R) in tandem and to preferentially activate immune cells expressing both targets. Simultaneous binding to both receptors results in enhanced IL-18 potency due to cis-signaling i.e., the engagement of PD-1, and blockade of PD-1/PD-L1 interaction, with concurrent IL-18 signaling through the IL-18R on the same cell. In transgenic mice engineered to express human PD-1, BPT567 induces significantly stronger anti-tumor efficacy relative to an anti-PD-1 antibody alone, a non-targeted IL-18 immunoconjugate alone or the combination of the two agents. BPT567 has demonstrated anti-tumor activity in both immune checkpoint inhibitor (ICI)-sensitive and ICI-resistant non-clinical tumor models. As a result of its high anti-tumor potency and relative tumor selectivity demonstrated in non-clinical tumor models, BPT567 is designed to induce lower systemic IL-18R-mediated activation side effects compared to non-targeted IL-18 agents when administered at efficacious doses.

BPT567 is entering a first-in-human phase 1a/1b study in patients with locally advanced or metastatic solid tumors.

BPT331TAP
(PD1-IL2TAP)

PD1-IL2TAP consists of Bright Peak’s enhanced IL-2 payload chemically conjugated to LZM009, an anti-PD-1 antibody now in late-stage clinical development, with an additional moiety that enables the IL-2 payload to be conditionally activated when encountering the tumor microenvironment (tumor activated payload or "TAP") for a potentially expanded therapeutic window and greater safety margin.

 

MENU '